Drug Shortage Report for TEVA-IRBESARTAN HCTZ
| Report ID | 101725 |
| Drug Identification Number | 02330512 |
| Brand name | TEVA-IRBESARTAN HCTZ |
| Common or Proper name | IRBESARTAN/HCTZ 150/12.5MG TAB |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | HYDROCHLOROTHIAZIDE IRBESARTAN |
| Strength(s) | 12.5MG 150MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 100 |
| ATC code | C09DA |
| ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2019-12-18 |
| Estimated end date | 2021-09-30 |
| Actual end date | 2021-09-09 |
| Shortage status | Resolved |
| Updated date | 2021-09-10 |
| Company comments | Allocating 100% of Teva market share from July to October 2020. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v14 | 2020-05-01 | French | Compare |
| v13 | 2020-05-01 | English | Compare |
| v12 | 2020-04-23 | French | Compare |
| v11 | 2020-04-23 | English | Compare |
| v10 | 2020-04-09 | French | Compare |
| v9 | 2020-04-09 | English | Compare |
| v8 | 2020-03-05 | French | Compare |
| v7 | 2020-03-05 | English | Compare |
| v6 | 2020-01-30 | French | Compare |
| v5 | 2020-01-30 | English | Compare |
| v4 | 2020-01-09 | French | Compare |
| v3 | 2020-01-09 | English | Compare |
| v2 | 2019-12-19 | French | Compare |
| v1 | 2019-12-19 | English | Compare |